The systemic mediator-associated response test identifies patients in failed sepsis clinical trials among whom novel drugs reduce mortality

Journal of Trauma - Injury, Infection and Critical Care

Volumn 71, Issue 5, 2011, Pages 1406-1414

  Slotman, Gus J ^a,b  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b OUR LADY OF LOURDES MEDICAL CENTER   (United States)

Author keywords

Clinical trials; Outcomes; Severe sepsis; Shock

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; E5 ENDOTOXIN ANTIBODY; ENDOTOXIN ANTIBODY; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; PLACEBO; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL (TOPIC); DRUG EFFECT; HUMAN; INFLAMMATION; MORTALITY; PATIENT IDENTIFICATION; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK; TREATMENT OUTCOME;

CHI-SQUARE DISTRIBUTION; CLINICAL LABORATORY TECHNIQUES; HUMANS; LOGISTIC MODELS; MODELS, THEORETICAL; PLACEBOS; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SEPSIS; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE;

EID: 81455135485     PISSN: 00225282     EISSN: 15298809     Source Type: Journal    
DOI: 10.1097/TA.0b013e3182159c61     Document Type: Article

References (23)

1. Bone RC, Fisher CJ, Clemmer P, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med. 1987;317:653-659.
2. Bone RC, Fisher CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA. The sepsis syndrome: a valid clinical entity. Methylprednisolone Severe Sepsis Study Group. Crit Care Med. 1989;17:389-393. (Pubitemid 19136902)
3. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101: 1644-1655.
4. Panacek E, Marshall JC, Fischkoff S, et al. Neutralization of TNF by a monoclonal antibody improves survival and reduces organ dysfunction in human sepsis: results of the MONARCS trial. Chest. 2000;118:88S.
5. Bernard GR, Vincent J-L, Laterre P-F, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699-709. (Pubitemid 32204987)
6. Slotman GJ. Multivariate regression modeling for the prediction of inflammation, systemic pressure and end-organ function in severe sepsis. Shock. 1997;8:225-231. (Pubitemid 127654331)
7. Slotman GJ. Multivariate regression modeling for the prediction of plasma eicosanoid and cytokine concentrations in patients with severe sepsis. J Surg Outcomes. 1998;1:24-30.
8. Slotman GJ. Prospectively validated predictions of shock and organ failure in individual septic surgical patients: the systemic mediator associated response test. Crit Care. 2000;4:319-326.
9. Bone RC, Balk RA, Fein AM, et al. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. Crit Care Med. 1995;23:994-1006.
10. Fisher CJ, Dhainaut JFA, Opal SM, et al. Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome. JAMA. 1994;271:1836-1843.
11. Abraham E, Wunderink R, Silverman H, et al. Monoclonal antibody to human tumor necrosis factor alpha (TNF-MAb): efficacy and safety in patients with the sepsis syndrome. JAMA. 1995;273:934-941.
12. Abraham E, Anzueto A, Gutierrez G, et al. Double-blind randomized controlled trial of monoclonal antibody to human tumor necrosis factor in treatment of septic shock. Lancet. 1998;351:929-923.
13. Opal S, Laterre PF, Abraham E, et al. Recombinant human plateletactivating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. Crit Care Med. 2004;32:332-341. (Pubitemid 38234108)
14. SAS Institute. SAS/STAT user's guide, version 6. 4th ed. Cary, NC: SAS Institute; 1994.
15. Opal SM, Fisher CJ, Dhainaut JFA, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, doubleblind, placebo-controlled, multicenter trial. Crit Care Med. 1997;25:115-123.
16. Angus DC, Birmingham MC, Balk RA, et al. E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis. A randomized controlled trial. JAMA. 2000;283:1723-1730. (Pubitemid 30196213)
17. Marshall JC, Foster D, Vincent J-L, et al. Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. J Infect Dis. 2004;190:527-534. (Pubitemid 38982092)
18. Tidswell M, Tillis W, LaRosa SP, et al. Phase II trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist in patients with sever sepsis. Crit Care Med. 2010;38:72-83.
19. Rice TW, Wheeler AP, Morris PE, et al. Safety and efficacy of affinitypurified, anti-tumor necrosis factor-ovine fab for injection (CytoFab) in severe sepsis. Crit Care Med. 2006;34:2271-2281. (Pubitemid 44260009)
20. Greenman RL, Schein RMH, Martin MA, et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA. 1991;266:1097-1102.
21. Dhainaut JFA, Tenaillon A, Hemmer M. Confirming phase III clinical trial to study the efficacy of a PAF antagonist, BN 52021, in reducing mortality of patients with severe gram-negative sepsis. Abst Am J Respir Crit Care Med. 1995;151:A447.
22. Dhainaut JFA, Tenaillon A, LeTuizo Y. Platelet activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Crit Care Med. 1997;25:115-123.
23. Pittet D, Harbarth S, Suter PM, et al. Impact of immunomodulating therapy on morbidity in patients with severe sepsis. Am J Respir Crit Care Med. 1999;160:852-857. (Pubitemid 29442020)